Zobrazeno 1 - 10
of 231
pro vyhledávání: '"José V Castell"'
Autor:
Ernesto López-Pascual, Ivan Rienda, Judith Perez-Rojas, Anna Rapisarda, Guillem Garcia-Llorens, Ramiro Jover, José V. Castell
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 10, p 5203 (2024)
Drug induced fatty liver disease (DIFLD) is a form of drug-induced liver injury (DILI), which can also be included in the more general metabolic dysfunction-associated steatotic liver disease (MASLD), which specifically refers to the accumulation of
Externí odkaz:
https://doaj.org/article/f86504396c4649ed9255bfce37a424bc
Autor:
Guillem Garcia-Llorens, Teresa Martínez-Sena, Eugenia Pareja, Laia Tolosa, José V. Castell, Roque Bort
Publikováno v:
Stem Cell Research & Therapy, Vol 14, Iss 1, Pp 1-19 (2023)
Abstract Background High-throughput pharmaco-toxicological testing frequently relies on the use of established liver-derived cell lines, such as HepG2 cells. However, these cells often display limited hepatic phenotype and features of neoplastic tran
Externí odkaz:
https://doaj.org/article/62a962e9da144657bf30508219281295
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 5, p 3003 (2024)
Drug-induced liver injury (DILI) is a serious adverse hepatic event presenting diagnostic and prognostic challenges. The clinical categorization of DILI into hepatocellular, cholestatic, or mixed phenotype is based on serum alanine aminotransferase (
Externí odkaz:
https://doaj.org/article/66f829bb90be46c9af7a010df82a943d
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Drug hepatotoxicity assessment is a relevant issue both in the course of drug development as well as in the post marketing phase. The use of human relevant in vitro models in combination with powerful analytical methods (metabolomic analysis) is a pr
Externí odkaz:
https://doaj.org/article/9edcedea08d04a0ba85d5c79e9afb9c5
Autor:
Álvaro Pérez-Rubio, Polina Soluyanova, Erika Moro, Guillermo Quintás, Iván Rienda, María Dolores Periañez, Andrés Painel, José Vizuete, Judith Pérez-Rojas, José V. Castell, Ramón Trullenque-Juan, Eugenia Pareja, Ramiro Jover
Publikováno v:
Nutrients, Vol 15, Iss 14, p 3187 (2023)
Bariatric surgery (BS) has several benefits, including resolution of non-alcoholic fatty liver disease (NAFLD) in many patients. However, a significant percentage of patients do not experience improvement in fatty liver after BS, and more than 10% de
Externí odkaz:
https://doaj.org/article/a170d0eaefee49e2953c33f3d1091aed
Autor:
Maria Ballester, Miguel Bolonio, Ramon Santamaria, José V. Castell, Carmen Ribes-Koninckx, Roque Bort
Publikováno v:
Stem Cell Research & Therapy, Vol 10, Iss 1, Pp 1-10 (2019)
Abstract Background Human fibroblasts can be reprogrammed into induced hepatocyte-like cells through the expression of a set of transcription factors. Although the generation of induced hepatocyte-like cells by HNF4A, HNF1A, and FOXA3 expression has
Externí odkaz:
https://doaj.org/article/928f04632cba40588ff7bbdfc65d83d6
Autor:
Teresa Martínez-Sena, Erika Moro, Marta Moreno-Torres, Guillermo Quintás, Jan Hengstler, José V. Castell
Publikováno v:
Martínez-Sena, Teresa Moro, Erika Moreno Torres, Marta Quintás Soriano, Guillermo Hengstler, Jan G. Castell, José V. 2023 Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved Archives of Toxicology 97 1723 1738
Toxicity studies, among them hepatotoxicity, are key throughout preclinical stages of drug development to minimise undesired toxic effects that might eventually appear in the course of the clinical use of the new drug. Understanding the mechanism of
Autor:
Guillermo Quintás, Florian Caiment, Iván Rienda, Judith Pérez-Rojas, Eugenia Pareja, José V. Castell, Ramiro Jover
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 16, p 9298 (2022)
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease worldwide, but a reliable non-invasive method to quantify liver steatosis in primary healthcare is not available. Circulating microRNAs have been proposed a
Externí odkaz:
https://doaj.org/article/697605491f3b42cba242a82d0d4e23e6
Publikováno v:
Metabolites, Vol 12, Iss 6, p 564 (2022)
Drug-induced liver injury (DILI) is one of the most frequent adverse clinical reactions and a relevant cause of morbidity and mortality. Hepatotoxicity is among the major reasons for drug withdrawal during post-market and late development stages, rep
Externí odkaz:
https://doaj.org/article/e74f11917edd4c7186dfb2cce3b13d21
Autor:
Vanessa Baier, Henrik Cordes, Christoph Thiel, José V. Castell, Ulf P. Neumann, Lars M. Blank, Lars Kuepfer
Publikováno v:
Frontiers in Physiology, Vol 10 (2019)
Drug-induced liver injury (DILI) is a matter of concern in the course of drug development and patient safety, often leading to discontinuation of drug-development programs or early withdrawal of drugs from market. Hepatocellular toxicity or impairmen
Externí odkaz:
https://doaj.org/article/e570eacc0c9a436fa107a7f433af15bd